Evaluation of Polymyxin B as a Novel Vaccine Adjuvant and Its Immunological Comparison with FDA-Approved Adjuvants
The adjuvant activity of Polymyxin B across various vaccine platforms is significantly comparable to FDA-approved adjuvants, which is a critical requirement for generating T cell responses such as helper T cell and cytotoxic CD8+ T cell responses.
Authors
- Dedeepya Pasupuleti
- Priyal Bagwe (ORCID: https://orcid.org/0000-0001-7151-5018)
- Emmanuel Adediran
- Nigel D’Souza (ORCID: https://orcid.org/0000-0002-3286-7333)
- Tanisha Arte
- Martin J. D’Souza
- Mahek Gulani
- Yash Harsoda
Institutions
- Mercer University (US)
- Mercer University Health Sciences Center (US)
- Larkin University (US)
- Memorial Health University Medical Center (US)
Publication Details
- Journal
- Vaccines
- Published
- 2025-12-09
- DOI
- https://doi.org/10.3390/vaccines13121232
- Citations
- 1
- Primary Topic
- vaccines and immunoinformatics approaches
- Type
- article
- Field-Weighted Citation Impact
- 0.81